Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)

被引：0
|
作者：
Aransay, N. Reguart [1 ]
Sanchez, J. [1 ]
Vidal, O. J. Juan [2 ]
Domingo, M. Aguilo [3 ]
Arriola, E. [4 ]
Lopez, C. [2 ]
Botella, X. [3 ]
Cots, F. [4 ]
Montironi, C. [5 ]
Palanca, S.
Borras, E. [3 ]
Pinto, L. Masfarre [4 ]
Planellas, L. [6 ]
Vila, A. Lloansi [6 ]
机构：
[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[2] Hosp Univ Politecn La Fe, Dept Med Oncol, Valencia, Spain
[3] Hosp Terrassa Consorci Sanitari Terrassa, Med Oncol, Terrassa, Spain
[4] Hosp Mar Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
[5] Hosp Clin Barcelona, Pathol, Barcelona, Spain
[6] Amgen Spain, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2442
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1410P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN
    Fernandez-Barcelo, C.
    Abbas, I
    Botella, X.
    Aguilo Domingo, M.
    Cots, F.
    Siles Cuesta, C.
    Arriola, E.
    Gas Lopez, M. E.
    Lopez Gomez, C.
    Juan-Vidal, O.
    Planellas, L.
    Lloansi, A.
    Sanchez, J.
    Reguart, N.
    Sampietro-Colom, L.
    VALUE IN HEALTH, 2023, 26 (12) : S521 - S521
  • [2] Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation
    Jaenne, Pasi A.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Heist, Rebecca S.
    Ou, Sai-Hong I.
    Pacheco, Jose M.
    Johnson, Melissa L.
    Sabari, Joshua K.
    Leventakos, Konstantinos
    Yau, Edwin
    Bazhenova, Lyudmila
    Negrao, Marcelo V.
    Pennell, Nathan A.
    Zhang, Jun
    Anderes, Kenna
    Der-Torossian, Hirak
    Kheoh, Thian
    Velastegui, Karen
    Yan, Xiaohong
    Christensen, James G.
    Chao, Richard C.
    Spira, Alexander I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (02) : 120 - 131
  • [3] First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation
    De, Surya K.
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (03) : 266 - 272
  • [4] KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
    Mok, Tony S. K.
    Yao, Wenxiu
    Duruisseaux, Michael
    Doucet, Ludovic
    Azkarate Martinez, Aitor
    Gregorc, Vanesa
    Juan-Vidal, Oscar
    Lu, Shun
    De Bondt, Charlotte
    de Marinis, Filippo
    Linardou, Helena
    Kim, Young-Chul
    Jotte, Robert M.
    Felip, Enriqueta
    Lo Russo, Giuseppe
    Reck, Martin
    Michenzie, Mary F.
    Yang, Wenjing
    Meade, Julie N.
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8509 - LBA8509
  • [5] Phase I study of D-1553 to assess safety and efficacy in patients with non-small cell lung cancer (NSCLC) harboring KRASG12C mutation.
    Jian, Hong
    Song, Zhenbo
    Zhang, Yiping
    Li, Kunyan
    Yang, Nong
    Moore, Melissa
    Wang, Pingli
    Zhao, Yanqiu
    Gong, Yi
    Underhill, Craig
    Kim, Sang-We
    Yang, Cheng-Ta
    Xiang, Ziyong
    Shi, Zhe
    Zhang, Ling
    Wang, Yaolin
    Lu, Shun
    CANCER RESEARCH, 2022, 82 (12)
  • [6] KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naive, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
    Garassino, M. C.
    Theelen, W. S. M. E.
    Jotte, R.
    Laskin, J.
    De Marinis, F.
    Aguado, C.
    Badin, F. B.
    Chmielewska, I.
    Hochmair, M. J.
    Lu, S.
    Nadal, E.
    Ostoros, G.
    Felip, E.
    Spira, A. I.
    Lane, C. M.
    He, J.
    Chao, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1309 - S1310
  • [7] Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
    Torres-Jimenez, Javier
    Espinar, Javier Baena
    de Cabo, Helena Bote
    Berjaga, Maria Zurera
    Esteban-Villarrubia, Jorge
    Fraile, Jon Zugazagoitia
    Paz-Ares, Luis
    DRUGS, 2024, 84 (05) : 527 - 548
  • [8] KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
    Spira, Alexander I.
    Riely, Gregory J.
    Gadgeel, Shirish M.
    Heist, Rebecca Suk
    Ou, Sai-Hong Ignatius
    Pacheco, Jose Maria
    Johnson, Melissa Lynne
    Sabari, Joshua K.
    Leventakos, Konstantinos
    Yau, Edwin
    Bazhenova, Lyudmila
    Negrao, Marcelo Vailati
    Pennell, Nathan A.
    Zhang, Jun
    Velastegui, Karen
    Christensen, James G.
    Yan, Xiaohong
    Anderes, Kenna Lynn
    Chao, Richard C.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
    Liu, Yan
    Li, Hui
    Zhu, Jing
    Zhang, Yang
    Liu, Xianhong
    Li, Rixin
    Zhang, Qiang
    Cheng, Ying
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2447 - 2454
  • [10] KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation
    Riely, G. J.
    Ou, S-H. I.
    Rybkin, I.
    Spira, A.
    Papadopoulos, K.
    Sabari, J. K.
    Johnson, M.
    Heist, R. S.
    Bazhenova, L.
    Barve, M.
    Pacheco, J. M.
    Velastegui, K.
    Cilliers, C.
    Olson, P.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S751 - S752
12345